Lenvima targets multiple receptor tyrosine kinases involved in tumor angiogenesis and cancer progression. By inhibiting these pathways, it may help slow tumor growth and limit the blood supply that tumors need to grow and spread.
Oncology
Showing all 23 results
-
-
ALECENSA (Alectinib)
ALECENSA (Alectinib): Targeted Treatment for ALK-Positive Non-Small Cell Lung Cancer
-
Anlotinib Hydrochloride
Anlotinib Hydrochloride
Anlotinib Hydrochloride is an oral multi-target tyrosine kinase inhibitor (TKI) used primarily in oncology. It works by blocking several signaling pathways involved in tumor growth and angiogenesis (the formation of new blood vessels that feed tumors).
-
Avastin (Bevacizumab)
Avastin is commonly used in combination with chemotherapy for the treatment of cancers such as colorectal cancer, non-small cell lung cancer, glioblastoma, kidney cancer, cervical cancer, and ovarian cancer.
-
Balversa (Erdafitinib)
Balversa (Erdafitinib) – Targeted Therapy for Advanced Urothelial Cancer
Precision Treatment for FGFR-Driven Cancer
Balversa (erdafitinib) is an oral targeted therapy designed for adults with locally advanced or metastatic urothelial carcinoma (bladder cancer) that has specific FGFR2 or FGFR3 genetic alterations and has progressed during or after platinum-containing chemotherapy.
It belongs to a class of medicines called FGFR kinase inhibitors, which work by blocking abnormal signals that help cancer cells grow.
-
Belzutifan/WELIREG
Welireg (generic name: belzutifan) is a prescription medication used in oncology, primarily for treating certain tumors associated with von Hippel–Lindau (VHL) disease and some advanced cancers.
-
Cabometyx (Cabozantinib)
Cabometyx is the brand name for cabozantinib, an oral targeted cancer therapy classified as a tyrosine kinase inhibitor (TKI). It works by blocking multiple receptor tyrosine kinases involved in tumor growth, angiogenesis (formation of new blood vessels), metastasis, and cancer progression.
-
Compound Fluorouracil Oral Solution
Fluorouracil (also written as 5-FU) is a chemotherapy medicine widely used in the treatment of several types of cancer. It belongs to a class of drugs called antimetabolites, which interfere with DNA and RNA synthesis, thereby stopping cancer cells from growing and dividing.
-
Enhertu (trastuzumab deruxtecan)
Enhertu is a HER2-directed antibody-drug conjugate designed to deliver targeted chemotherapy inside cancer cells, helping treat certain advanced solid tumors.
-
IMFINZI Injection (Durvalumab)
IMFINZI Injection (Durvalumab): An Advanced Immunotherapy for Cancer Treatment IMFINZI Injection contains durvalumab, a monoclonal antibody that belongs to a class of medicines known as immune checkpoint inhibitors. It is designed to help the body’s immune system recognize and attack cancer cells more effectively. Unlike traditional chemotherapy, which directly targets rapidly dividing cells, IMFINZI works…
-
Iressa (Gefitinib)
Iressa is a prescription cancer medicine used mainly in the treatment of non-small cell lung cancer (NSCLC), particularly in patients whose tumors have specific mutations in the epidermal growth factor receptor (EGFR) gene. What Iressa is used for Iressa is primarily prescribed for: Advanced or metastatic non-small cell lung cancer (NSCLC) Patients with EGFR mutation-positive…
-
KEYTRUDA (Pembrolizumab)
KEYTRUDA (Pembrolizumab): Advancing Cancer Care Through Immunotherapy
-
Kisqali (ribociclib)
Kisqali is a prescription medicine used in combination with endocrine therapy to treat certain types of breast cancer in adults. It is developed by Novartis and belongs to a class of medicines called CDK4/6 inhibitors.
-
Lenvima (Lenvatinib)
Lenvima targets multiple receptor tyrosine kinases involved in tumor angiogenesis and cancer progression. By inhibiting these pathways, it may help slow tumor growth and limit the blood supply that tumors need to grow and spread.
-
LORBRENA (lorlatinib)
LORBRENA is an advanced targeted therapy designed for adults diagnosed with ALK-positive metastatic non-small cell lung cancer (NSCLC).
-
Mekinist (Trametinib)
Mekinist (Trametinib): Uses, Benefits, and Important Safety Information
What Is Mekinist?
Mekinist (trametinib) is a prescription medication used in the treatment of certain types of cancer that have specific genetic mutations. It belongs to a class of targeted therapies known as MEK inhibitors, which work by blocking signals that help cancer cells grow and divide.
Healthcare providers may prescribe Mekinist alone or in combination with other targeted therapies, depending on the patient’s diagnosis and molecular testing results.
-
Rybrevant® (amivantamab)
Rybrevant (amivantamab) is a prescription medication designed to treat certain adults with non-small cell lung cancer (NSCLC) whose tumors have specific genetic alterations in the EGFR gene.It is a bispecific antibody that targets both EGFR (epidermal growth factor receptor) and MET (mesenchymal-epithelial transition factor) pathways, which can contribute to tumor growth and survival.
-
Sorafenat (Sorafenib)
Sorafenib works by blocking specific enzymes (kinases) that help cancer cells grow and form new blood vessels. Liver cancer (hepatocellular carcinoma) Kidney cancer (renal cell carcinoma) Thyroid cancer (advanced, radioactive iodine–resistant)
-
Stivarga (Regorafenib)
Stivarga (regorafenib) is an oral prescription medication used to treat certain types of advanced cancers. It belongs to a class of targeted therapies known as multikinase inhibitors, which work by blocking specific proteins involved in tumor growth and the formation of new blood vessels that feed cancer cells.
-
TAFINLAR (dabrafenib)
TAFINLAR is a targeted therapy designed to help address cancers driven by specific BRAF gene mutations. By targeting abnormal signaling pathways involved in tumor growth, TAFINLAR® plays an important role in personalized treatment approaches for eligible patients.
-
XOLAIR® (Omalizumab)
XOLAIR® (Omalizumab)
Helping Patients Manage Allergic and Inflammatory Conditions
XOLAIR® (omalizumab) is a prescription biologic medicine designed to target immunoglobulin E (IgE), a key driver of allergic responses. By reducing the activity of IgE, XOLAIR helps address the underlying cause of certain allergic and inflammatory conditions, supporting better disease control and improved quality of life.
-
YERVOY (Ipilimumab)
YERVOY® (ipilimumab) is an immunotherapy medicine used to treat several types of cancer. It belongs to a class of drugs known as immune checkpoint inhibitors and works by helping the body’s immune system recognize and attack cancer cells.
-
ZEPZELCA (lurbinectedin)
ZEPZELCA is a prescription medication used in adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.